• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Aug. 19, 2013

View Archived Issues

Earnout Pan Out? Biomarin's Deals Progressing Years Later

The buyout of Talon Therapeutics Inc. by Spectrum Pharmaceuticals Inc. for $11.3 million in cash up front and contingent value rights (CVRs) for up to $195 million indicate that the earnout deal remains alive and well in biotech. Read More

Another Day and Another Biotech IPO: Ophthotech Files

Eye disease specialist Ophthotech Corp. became the 30th biotech this year to pursue an initial public offering (IPO), seeking to raise $85 million, according to its Form S-1 filed with the SEC Friday. The company did not disclose the number of shares or price range in the offering. Read More

Sophiris Bio Cuts Initial Public Offering Price

Following a 1-for-52 reverse stock split of common shares traded on the Toronto Stock Exchange, Sophiris Bio Inc., of La Jolla, Calif., slashed its planned public offering price from $13 per share to $5 per share, while increasing the number of shares offered to maintain a target of $65 million in gross proceeds. Read More

'Best of Unigene' Lands in Hands of Start-up Enteris

Crushing debt forced Unigene Laboratories Inc. into bankruptcy earlier this year, but its promising Peptelligence delivery technology has found a new home in start-up Enteris Biopharma Inc., which launched recently to develop oral formulations of both peptide drugs and currently injectable-only small molecules. Read More

PKAN Logs Retrophin $25M; Autism/Schizo Bid Lies Ahead, Too

With $25 million pledged from a stock sale to institutional investors, rare-disease specialist Retrophin Inc. signed a deal with an unidentified pharma firm for an option to license its autism/schizophrenia drug and said plans for a potentially pivotal trial are on track for RE-021, the firm's dual-acting receptor antagonist of angiotensin and endothelin receptors, as a therapy for focal segmental glomerulosclerosis (FSG). Read More

Study Shows the Reason for Aging Brain's Vulnerability

Alzheimer's disease is characterized – among other things – by a dramatic upregulation of the complement cascade, as well as by massive loss of neural connection points or synapses. Read More

Other News To Note

• Cadence Pharmaceuticals Inc., of San Diego, said the U.S. Patent and Trademark Office (USPTO) has issued a non-final, initial office action in the ex parte reexamination of U.S. Patent No. 6,028,222, or the '222 patent, one of the two licensed patents covering Ofirmev (acetaminophen) injection. Read More

Clinic Roundup

• Prosonix, of Oxford, UK, completed patient dosing and follow-up in a Phase II study of PXS1002, a suspension formulation of long-acting muscarinic antagonist (LAMA), glycopyrronium bromide, which is being developed for chronic obstructive pulmonary disease (COPD). Read More

Stock Movers

Read More

Pharma: Other News To Note

• The FDA approved Glaxosmithkline plc's Flulaval Quadrivalent (Influenza Virus Vaccine) for immunization of people older than 3 for seasonal influenza virus subtypes A and B. Flulaval is the London-based GSK's second intramuscular quadrivalent vaccine approved by the FDA. Read More

Bench Press: BioWorld Looks at Translational Medicine

Scientists at the University of Texas Health Science Center at San Antonio have discovered why amplifications of certain parts of chromosomes 17 and 20 are associated with a poor prognosis in breast cancer. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 5, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 5, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • DNA mutations or genetic disorder concept art

    Regenxbio’s Duchenne gene therapy data positive as shares falter

    BioWorld
    Regenxbio Inc.’s gene therapy in treating Duchenne muscular dystrophy (DMD) produced positive initial phase I/II results from its first five patients. However,...
  • Woman holding neck

    Merus combo trounces Keytruda in head-and-neck phase II

    BioWorld
    Investor hopes rose sharply for Merus NV’s phase III trials – data should roll out next year – with bispecific antibody petosemtamab after mid-stage results...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe